This review from The Journal of Clinical Investigation examines the extensive impact of GLP-1 receptor agonists on the cardiovascular system. Preclinical research demonstrates that these therapies provide direct vascular protection by reducing inflammation and stabilizing atherosclerotic plaques, often independently of weight loss or glucose levels. In clinical settings, large-scale trials have confirmed that long-acting versions of these drugs significantly lower the risk of major adverse cardiovascular events, such as heart attacks and strokes. The text also highlights the emerging benefits for patients with heart failure, particularly those with the obesity-related preserved ejection fraction phenotype. Ultimately, the authors position these medications as a foundational treatment for reducing cardiovascular risk in individuals with type 2 diabetes, kidney disease, or obesity. This comprehensive overview bridges the gap between molecular mechanisms and real-world therapeutic outcomes in modern medicine.

Powered by Firstory Hosting